Know Cancer

forgot password

Quantitative Dynamic Contrast Enhanced Breast MRI

Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Quantitative Dynamic Contrast Enhanced Breast MRI

Our aim is to perform dynamic contrast enhanced (DCE) MRI on 150 patients during their
routine breast MRI examination at MSKCC. This will add extra 10 min scanning time to the
routine examination. High resolution (submillimeter) parametric maps of pathophysiologic
quantities, such as tumor vessel permeability, tumor perfusion, extracellular extravascular
volume fraction, will be generated from the DCE MRI data. These results will be correlated
with pathology to determine new pharmacokinetic threshold so that the negative predictive
value for benign lesions is close to 100%. The improvement in diagnostic specificity may
help to reduce unnecessary biopsies in the future.

Inclusion Criteria:

ยท scheduled for breast MRI interventional procedure for a known breast lesion.

Exclusion Criteria:

- patients who would be normally excluded from undergoing an MRI examination patients
with a pacemaker, aneurysm clip or any other condition that would warrant avoidance
of a strong magnetic field.

- patients who are unable to cooperate for an MRI, and/or have known reaction to
gadolinium contrast agent.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

To assess whether the new quantitative MRI method can discriminate between malignant and nonmalignant breast lesions among the lesions seen in conventional MRI.

Outcome Time Frame:

December 2008

Safety Issue:


Principal Investigator

Sunitha Thakur, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

September 2005

Completion Date:

September 2014

Related Keywords:

  • Breast Cancer
  • Breast Lesion
  • Lesion
  • Breast
  • Cancer
  • 05-091
  • Breast Neoplasms



Memorial Sloan-Kettering Cancer Center New York, New York  10021